anti-Heparin Cofactor II, mAb (74E5)

CHF 322.00
In stock
YIF-LF-MA0150100 µlCHF 322.00
More Information
Product Details
Synonyms HLS2; HCF2; HC-II; SERPIND1; Serpin D1; Heparin Cofactor 2; Heparin Cofactor II; Protease Inhibitor Leuserpin-2
Product Type Monoclonal Antibody
Properties
Clone 74E5
Isotype Mouse IgG2b κ
Immunogen/Antigen Protein purified from human plasma.
Application

ELISA
Western Blot (1:2,000)
IHC-P

Crossreactivity Human
Purity Detail Ammonium sulfate precipitation.
Formulation Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

Declaration Manufactured by AbFrontier
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS No
Product Specification Sheet
Datasheet Download PDF

Heparin cofactor II (HCII), a single chain glycoprotein with a MW of 65kDa, is a serine protease inhibitor that is synthesized by the liver and circulates in plasma. Heparin cofactor II inhibits thrombin by formation of a stable bimolecular complex, but has no activity against other proteases involved in coagulation or fibrinolysis. The rate at which HCII inhibits thrombin increases more than 1000-fold in the presence of heparin, heparan sulfate, or dermatan sulfate. Heparin cofactor II is unique among serine protease inhibitors in its ability to be stimulated by dermatan sulfate, and it binds to a minor subpopulation of dermatan sulfate oligosaccharides. Turnover studies of labeled HCII in humans suggest that 40% of the protein equilibrates with an extravascular compartment, but the distribution of HCII in various tissues has not been thoroughly investigated. Heparin cofactor II has been detected in the intima of normal human arteries, and the ability of dermatan sulfate in the arterial wall to stimulate HCII is decreased in atherosclerotic lesions. Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner. Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.

Product References

1) Tollefsen DM, (2004) Circulation vol.109(22): pp.2682-4. (General)
2) Tollefsen DM, (2002) Arch Pathol Lab Med. Vol.126(11) : pp.1394-400. (General)

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.